Staff Profile

Introduction

Please see my personal web site www.staff.ncl.ac.uk/philip.home for details of my academic and clinical activities. A full CV and publication list are available there.

Background

A full list of activities and positions is given on my personal website www.staff.ncl.ac.uk/philip.home

Other current roles

Public Governor, Newcastle upon Tyne NHS Trust

Previous Roles and Responsibilities

Vice-chair, Appraisals Committee, National Institute of Clinical Excellence
Chair, Clinical Guidelines Task Force, International Diabetes Federation
President, WorldWIDE Initiative for Diabetes Education

Qualifications

BA (Oxon) 1969; DPhil (Oxon) 1974; MA (Oxon) 1974;
BM, BCh (Oxon) 1976; MRCP(UK) 1978; DM (Oxon) 1991

Previous Positions

Vice-President, International Diabetes Federation
President, European Region, International Diabetes Federation

Research output

Please see publication list at www.staff.ncl.ac.uk/philip.home - h index 72, citations >30 000

Research Interests

International lead on many insulin and other diabetes drug developments and evaluations, new and established
International and UK lead on evidence-based diabetes guidelines

Other Expertise

Global diabetes care, structure of care delivery, health economic evaluation

Current Work

Professor of Diabetes Medicine, University of Newcastle upon Tyne.  Emeritus from February 2020

Future Research

Clinical trials in diabetes care

Esteem Indicators (see full CV on personal website)

Global lead on clinical trials
Global and UK lead on evidence-based diabetes guidelines
Membership of many pharmaceutical global advisory boards
Invited lecturer many international diabetes meetings 
Invited lecture many national overseas (and national UK) meetings 

Industrial Relevance

Member of many global advisory boards (diabetes / cardiovascular), and lead external advisor on a number of recent new diabetes pharmaceuticals of high clinical significance.

Undergraduate Teaching

Newcastle University lecturing in pharmacology and M Res

Postgraduate Teaching

Many international and overseas/UK national lectures and teach-ins every year.  Scientific organizer of international meetings including IDF Congress and World Clinical Trials in Diabetes (2018,2019)

• Home P, Mehta R. Insulin therapy development beyond 100 years. Lancet Diabetes Endocrinol 2021 2022, 9(10), 695-697.
• Home P. Can we find out if COVID-19 causes diabetes?. British Journal of Diabetes 2021, 21(1), 1-2.
• Home PD, Mehta R, Hafidh KAS, Gurova OY, Alvarez A, Serafini P, Pourrahmat M-M. Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison. Diabetes, Obesity and Metabolism 2021, 23(12), 2660-2669.
• Home P. Future directions in insulin therapy. Metabolism: Clinical and Experimental 2021, 124, 154889.
• Itzhak B, Home P. Heart failure management; a perspective from diabetes care. Diabetes Research and Clinical Practice 2021, 176, 108849.
• Riddle MC, Gerstein HC, Home PD. Lingering effects of hyperglycemia in recently diagnosed diabetes during long-term follow-up of the dcct/edic and ukpds cohorts: More evidence that early control matters. Diabetes Care 2021, 44(10), 2212-2215.
• Akirov A, Cahn A, Del Prato S, Home P, Van Gaal L, Chan J, Ning G, Raz I. Tackling obesity during the COVID-19 pandemic. Diabetes/Metabolism Research and Reviews 2021, 37(3), e3393.
• Home P. The evolution of insulin therapy. Diabetes Research and Clinical Practice 2021, 175, 108816.
• Lu J, Home PD, Zhou J. Comparison of multiple cut points for time in range in relation to risk of abnormal carotid intima-media thickness and diabetic retinopathy. Diabetes Care 2020, 43(8), e99-e101.
• Home PD, Aroda VR, Blonde L, Guyot P, Shaunik A, Fazeli MS, Goswami H, Kalra S, Pourrahmat M-M. Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison. Diabetes, Obesity and Metabolism 2020, 22(11), 2170-2178.
• Home P. How Valid Are the New Hypoglycemia Definitions for Use in Clinical Trials?. Diabetes care 2020, 43(2), 272-274.
• Rosenstock J, Nino A, Soffer J, Erskine L, Acusta A, Dole J, Carr MC, Mallory J, Home P. Impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: A randomized trial. Diabetes Care 2020, 43(10), 2509-2518.
• Home P, Blonde L, Kalra S, Ji L, Guyot P, Brulle-Wohlhueter C, Murray E, Shah R, Sayre T, Shaunik A. Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis. Diabetes, Obesity and Metabolism 2020, 22(11), 2179-2188.
• Home P, Itzhak B. Is Insulin Therapy Safe?. American Journal of Therapeutics 2020, 27(1), e106-e114.
• Home P. Cardiovascular outcome trials of glucose-lowering medications: an update. Diabetologia 2019, 62(3), 357-369.
• Owens DR, Landgraf W, Frier BM, Zhang M, Home PD, Meneghini L, Bolli GB. Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%. Diabetes, Obesity and Metabolism 2019, 21(2), 321-329.
• Home PD. Controversies for Glucose Control Targets in Type 2 Diabetes: Exposing the Common Ground. Diabetes Care 2019, 42(9), 1615-1623.
• Shavadia JS, Sharma A, Gu X, Neaton J, DeLeve L, Holmes D, Home P, Eckel RH, Watkins PB, Granger CB. Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program. Clinical Trials 2019, 16(3), 253-262.
• Klonoff DC, Aron D, Cohen RM, Home P, John WG, Little RR, Nathan DM, Sacks DB. The Need for Accuracy in Hemoglobin A1c Proficiency Testing: Why the Proposed CLIA Rule of 2019 Is a Step Backward. Journal of Diabetes Science and Technology 2019, (ePub ahead of Print).
• Wang C-Y, Neil DL, Home P. 2020 vision – An overview of prospects for diabetes management and prevention in the next decade. Diabetes Research and Clinical Practice 2018, 143, 101-112.
• Home P, Shankar RR, Gantz I, Iredale C, O'Neill EA, Jain L, Pong A, Suryawanshi S, Engel SS, Kaufman KD, Lai E. A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes. Diabetes Research and Clinical Practice 2018, 138, 253-261.
• Home P, Derwahl K-M, Ziemen M, Wernicke-Panten K, Pierre S, Kirchhein Y, Garg SK. Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes. Diabetes Technology and Therapeutics 2018, 20(2), 160-170.
• Riddle MC, Bolli GB, Avogaro A, Alvarez MG, Merino-Trigo A, Boelle-Le Corfec E, Home PD. Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events. Diabetes and Metabolism 2018, 44(4), 333-340.
• Home P, Calvi-Gries F, Blonde L, Pilorget V, Berlingieri J, Freemantle N. Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study. Diabetes, Obesity and Metabolism 2018, 20(4), 921-929.
• Home P, Lachin J. Comment on Novodvorsky et al. Diurnal Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People With Type 1 Diabetes. Diabetes Care 2017;40:655–662. Diabetes Care 2018, 41(4), e64-e64.
• Home PD, Lam RLH, Carofano WL, Golm GT, Eldor R, Crutchlow MF, Marcos MC, Rosenstock J, Hollander PA, Gallwitz B. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial. Diabetes, Obesity and Metabolism 2018, 20(9), 2220-2228.
• Hollander PA, Carofano WL, Lam RLH, Golm GT, Eldor R, Crutchlow MF, Marcos MC, Rendell MS, Home PD, Gallwitz B, Rosenstock J. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial. Diabetes, Obesity and Metabolism 2018, 20(9), 2229-2237.
• Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, Riddle MC. Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4). Diabetes, Obesity and Metabolism 2018, 20(1), 121-128.
• Beyond A1C Writing Group. Need for regulatory change to incorporate beyond A1C glycemic metrics. Diabetes Care 2018, 41(6), e92-e94.
• Home P. A diabetes mellitus guideline gone wrong - the 2017 ACP update. Nature Reviews Endocrinology 2017, 13(4), 191-192.
• Home PD. Comment on Abd El Aziz et al., A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes, Obesity and Metabolism 2017, 9(2), 304-305.
• Home PD. Comment on Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. integrated health care delivery systems 2005–2011. Diabetes Care 2016: 39; 363–370. Diabetes Care 2017, 40(2), e25-e25.
• Bolli GB, Riddle MC, Bergenstal RM, Wardecki M, Goyeau H, Home PD. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial. Diabetes and Metabolism 2017, 43(4), 351-358.
• Hirsch IB, Martinez J, Dorsey ER, Finken G, Fleming A, Gropp C, Home P, Kaufer DI, Papapetropoulos S. Incorporating Site-Less Clinical Trials Into Drug Development: A Framework for Action. Clinical Therapeutics 2017, 39(5), 1064-1076.
• Blonde L, Marre M, Vincent M, Brette S, Pilorget V, Danchin N, Vespasiani G, Home P. Insulin regimens and glycemic control in different parts of Europe over 4 years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional study. Diabetes Research and Clinical Practice 2017, 133, 150-158.
• Schnell O, Barnard K, Bergenstal R, Bosi E, Garg S, Guerci B, Haak T, Hirsch IB, Ji L, Joshi SR, Kamp M, Laffel L, Mathieu C, Polonsky WH, Snoek F, Home P. Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting. Diabetes Technology and Therapeutics 2017, 19(7), 391-399.
• Home PD, Ahren B, Reusch JEB, Rendell M, Weissman PN, Cirkel DT, Miller D, Ambery P, Carr MC, Nauck MA. Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice 2017, 131, 49-60.
• Riddle MC, Home PD, Avogaro A, Alvarez MG, Merino-Trigo A, Grisoni ML, Glezer S, Bolli GB. A clinically defined nocturnal window for analysis of hypoglycemia: New insulin glargine 300U/ML (GLA-300) in type 2 diabetes (T2DM). In: 9th International Conference on Advanced Technologies & Treatments for Diabetes. 2016, Milan, Italy: Mary Ann Liebert, Inc. Publishers.
• Kumar A, Awata T, Bain SC, Ceriello A, Fulcher GR, Unnikrishnan AG, Arechavaleta R, Gonzalez-Galvez G, Hirose T, Home PD, Kaku K, Litwak L, Madsbad S, Pinget M, Mehta R, Mithal A, Tambascia M, Tibaldi J, Christiansen JS. Clinical use of the co-formulation of insulin degludec and insulin aspart. International Journal of Clinical Practice 2016, 70(8), 657-667.
• Riddle MC, Bolli GB, Home PD, Bergenstal RM, Ziemen M, Muehlen-Bartmer I, Wardecki M, Vinet L, Jeandidier N, Yki-Jarvinen H. Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes. Diabetes Technology & Therapeutics 2016, 18(4), 252-257.
• Giorgino F, Home PD, Tuomilehto J. Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?. Diabetes Care 2016, 39(Supplement 2), S187-S195.
• Christiansen JS, Home P, Kumar A. IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status. Expert Review of Endocrinology & Metabolism 2016, 11(2), 103-111.
• Freemantle N, Danchin N, Calvi-Gries F, Vincent M, Home PD. Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin. Diabetes, Obesity and Metabolism 2016, 18(2), 152-158.
• Home PD. A common fallacy of observational medication studies in diabetes. Diabetes, Obesity and Metabolism 2015, 17(4), 317-318.
• Cefalu WT, Bray GA, Home PD, Garvey WT, Klein S, Pi-Sunyer FX, Hu FB, Raz I, Van Gaal L, Wolfe BM, Ryan DH. Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2015, 38(8), 1567-1582.
• Home P, Miller D, Carr MC. Albiglutide provides effective glycaemic lowering across diabetes duration subgroups. In: 51st EASD Annual Meeting. 2015, Stockholm, Sweden: Springer.
• Home P, Baik SH, Galvez GG, Malek R, Nikolajsen A. An analysis of the cost-effectiveness of starting insulin detemir in insulin-naive people with type 2 diabetes. Journal of Medical Economics 2015, 18(3), 230-240.
• Heinemann L, Khatami H, McKinnon R, Home P. An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins. Diabetes Technology & Therapeutics 2015, 17(7), 510-526.
• Heinemann L, Home PD, Hompesch M. Biosimilar insulins: guidance for data interpretation by clinicians and users. Diabetes, Obesity and Metabolism 2015, 17(10), 911-918.
• Jones NP, Curtis PS, Home PD. Cancer and bone fractures in observational follow-up of the RECORD study. Acta Diabetologica 2015, 52(3), 539-546.
• Schnell O, Barnard K, Bergenstal R, Bosi E, Garg S, Guerci B, Haak T, Hirsch IB, Ji LN, Joshi SR, Kamp M, Laffel L, Mathieu C, Polonsky WH, Snoek F, Home P. Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research. Diabetes Care 2015, 38(9), 1627-1633.
• Brooks AM, Oram R, Home P, Steen N, Shaw JAM. Demonstration of an Intrinsic Relationship Between Endogenous C-Peptide Concentration and Determinants of Glycemic Control in Type 1 Diabetes Following Islet Transplantation. Diabetes Care 2015, 38(1), 105-112.
• Home PD, Shamanna P, Stewart M, Yang F, Miller M, Perry C, Carr MC. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes, Obesity and Metabolism 2015, 17(2), 179-187.
• Home PD, Dain MP, Freemantle N, Kawamori R, Pfohl M, Brette S, Pilorget V, Scherbaum WA, Vespasiani G, Vincent M, Balkau B. Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents. Diabetes Research and Clinical Practice 2015, 108(2), 350-359.
• Home PD, Bolli GB, Mathieu C, Deerochanawong C, Landgraf W, Candelas C, Pilorget V, Dain MP, Riddle MC. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity and Metabolism 2015, 17(1), 15-22.
• Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H, Home PD, Edition 3 Study Investigators. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes, Obesity and Metabolism 2015, 17(4), 386-394.
• Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, Riddle MC. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care 2015, 38(12), 2217-2225.
• Bolli GB, Riddle MC, Bergenstal RM, Sestakauskas K, Goyeau H, Home PD. New insulin glargine 300U/ml (Gla-300): glycaemic control and hypoglycaemia in insulin-naive people with Type 2 diabetes compared with glargine 100U/ml (Gla-100). In: Diabetes UK Professional Conference 2015. 2015, London, UK: Wiley-Blackwell.
• Home PD, Riddle MC, Bergenstal RM, Bolli GB, Wardecki M, Maroccia M, Yki-Jarvinen H. New insulin glargine 300U/ml in people with Type 2 diabetes using basal insulin plus oral glucose lowering drugs compared with glargine 100U/ml (EDITION 2): less nocturnal hypoglycaemia and weight gain. In: Diabetes UK Professional Conference 2015. 2015, London, UK: Wiley-Blackwell.
• Home PD, Yki-Jarvinen H, Bolli GB, Cissokho S, Riddle MC. New insulin glargine 300U/ml in Type 2 diabetes using basal plus meal-time insulin: sustained glycaemic control and less hypoglycaemia compared with glargine 100U/ml (EDITION 1). In: Diabetes UK Professional Conference 2015. 2015, London, UK: Wiley-Blackwell.
• Riddle MC, Yki-Jarvinen H, Bolli GB, Ziemen M, Muehlen-Bartmer I, Cissokho S, Home PD. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Diabetes, Obesity and Metabolism 2015, 17(9), 835-842.
• Home P. Pharmacokinetics and Pharmacodynamics of Biosimilar Insulins: Is Clamp Technology Fit for Purpose?. Diabetes Care 2015, 38(12), 2234-2236.
• Home PD. Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?. Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics 2015, 17(11), 1011-1020.
• Balkau B, Calvi-Gries F, Freemantle N, Vincent M, Pilorget V, Home PD. Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT study. Diabetes Research and Clinical Practice 2015, 108(3), 432-440.
• Shafie AA, Gupta V, Baabbad R, Hammerby E, Home P. An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naive people with poorly controlled type 2 diabetes. Diabetes Research and Clinical Practice 2014, 106(2), 319-327.
• Cefalu WT, Buse JB, Del Prato S, Home PD, LeRoith D, Nauck MA, Raz I, Rosenstock J, Riddle MC. Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2014, 37(9), 2647-2659.
• Balkau B, Home PD, Vincent M, Marre M, Freemantle N. Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin. Diabetes Care 2014, 37(8), 2108-2113.
• Balkau B, Home PD, Vincent M, Marre M, Freemande N. Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin. Diabetes Care 2014;37:2108-2113. Diabetes Care 2014, 37(12), E266-E266.
• Dolinar RO, Edelman S, Heinemann L, Home P, Goyal S, Polonsky WH, Schellekens H. Impact of biosimilar insulins on clinical practice: Meeting report. Journal of Diabetes Science and Technology 2014, 8(1), 179-185.
• Home P, Riddle M, Cefalu WT, Bailey CJ, Bretzel RG, del Prato S, Leroith D, Schernthaner G, van Gaal L, Raz I. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?. Diabetes Care 2014, 37(6), 1499-1508.
• Mihaljevic R, Ritzel R, Riddle M, Bolli G, Ziemen M, Muehlen-Bartmer I, Bizet F, Home P. Neues Insulin glargin U300: Blutzuckerkontrolle undHypoglykämiehäufigkeit bei Patienten mit Typ-2-Diabetes und einem Therapieschema aus Basal- undMahlzeiteninsulin (EDITION I) [New Insulin glargin U300: Blood Sugar Control and Hypoglycemic Frequency for Patients with Type-2-Diabetes and a Treatment Scheme from Basal- and Meal Insulin (EDITION I)]. In: Jahrestagung der Österreichischen Diabetes Gesellschaft. 2014, Salzburg: Springer.
• Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1). Diabetes Care 2014, 37(10), 2755-2762.
• Home PD, Shen CD, Hasan MI, Latif ZA, Chen JW, Galvez GG. Predictive and Explanatory Factors of Change in HbA_1c in a 24-Week Observational Study of 66,726 People With Type 2 Diabetes Starting Insulin Analogs. Diabetes Care 2014, 37(5), 1237-1245.
• Home P, Riddle M, Cefalu WT, Bailey CJ, Bretzel RG, del Prato S, Leroith D, Schernthaner G, van Gaal L, Raz I. Response to Comment on Home et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care 2014; 37: 1499-1508. Diabetes Care 2014, 37(11), E247-E247.
• Hajjaji I, Shah S, Li Y, Prusty V, Benabbas Y, Home PD. Safety, Tolerability, and Efficacy of Insulin Aspart in People with Type 2 Diabetes, as Biphasic Insulin Aspart or with Basal Insulin: Findings from the Multinational, Non-Interventional A₁chieve Study. Diabetes Therapy 2014, 5(1), 113-126.
• Home PD. The vexed question of hypoglycaemia and health economics. Diabetes, Obesity & Metabolism 2014, 16(4), 289-293.
• Stewart M, Home P, Yang F, Perry C, Carr MC. 52-week efficacy of albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in patients with type 2 diabetes: HARMONY 5 study. In: 48th General Assembly of the European Association for the Study of Diabetes. 2013, Berlin Messe, Germany: Springer.
• Freemantle N, Balkau B, Home PD. A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes. Diabetes, Obesity and Metabolism 2013, 15(12), 1120-1127.
• Riddle MC, Aronson R, Home P, Marre M, Niemoeller E, Miossec P, Ping L, Ye J, Rosenstock J. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013, 36(9), 2489-2496.
• Shah S, Yang WY, Hasan MI, Malek R, Bech OM, Home P. Biphasic Insulin Aspart 30 in Insulin-Naive People with Type 2 Diabetes in Non-western Nations: Results from a Regional Comparative Multinational Observational Study (A₁chieve). Diabetes Technology & Therapeutics 2013, 15(11), 954-963.
• Home P, Haddad J, Latif ZA, Soewondo P, Benabbas Y, Litwak L, Guler S, Chen JW, Zilov A. Comparison of National/Regional Diabetes Guidelines for the Management of Blood Glucose Control in non-Western Countries. Diabetes Therapy 2013, 4(1), 91-102.
• Home P, Dain MP, Freemantle N, Kawamori R, Pfohl M, Pilorget V, Scherbaum W, Vespasiani G, Vincent M, Balkau B. Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents. In: 49th Annual Meeting of the European Association for the Study of Diabetes. 2013, Barcelona, Spain: Springer.
• Home PD, Meneghini LF, Wendisch U, Ratner RE, Johansen T, Christensen TE, Jendle J, Roberts AP, Birkeland KI. Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes. Diabetes Technology and Therapeutics 2013, 15(Suppl. 1), 716-720.
• Home P. Insulin Therapy and Cancer. Diabetes Care 2013, 36, S240-S244.
• Lopes RD, Dickerson S, Hafley G, Burns S, Tourt-Uhlig S, White J, Newby K, Komajda M, McMurray J, Bigelow R, Home PD, Mahaffey KW. Methodology of a re-evaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct. American Heart Journal 2013, 166(2), 208-216.
• Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD. New Insulin Glargine Formulation: Glucose Control and Hypoglycaemia in People with Type 2 Diabetes Using Basal and Mealtime Insulin (EDITION I). In: 48th Annual Meeting of the European Association for the Study of Diabetes (EASD). 2013, Berlin Messe, Germany: Springer.
• Home P. Observational research: an integral part of enhancing diabetes management in south-east Asia. Diabetes Research and Clinical Practice 2013, 100(Suppl. 1), S1-S2.
• Raz I, Riddle MC, Rosenstock J, Buse JB, Inzucchi SE, Home PD, Del Prato S, Ferrannini E, Chan JCN, Leiter LA, LeRoith D, DeFronzo R, Cefalu WT. Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care 2013, 36(6), 1779-1788.
• Hall GC, McMahon AD, Dain MP, Wang E, Home PD. Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK. Diabetic Medicine 2013, 30(6), 681-686.
• Mahaffey KW, Hafley G, Dickerson S, Burns S, Tourt-Uhlig S, White J, Newby LK, Komajda M, McMurray J, Bigelow R, Home PD, Lopes DR. Results of a re-evaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal 2013, 166(2), 240-249.
• Home PD, Latif ZA, González-Gálvez G, Prusty V, Hussein Z. The effectiveness and safety of beginning insulin aspart together with basal insulin in people with type 2 diabetes in non-Western nations: Results from the A₁chieve observational study. Diabetes Research and Clinical Practice 2013, 101, 326-332.
• Home P. Validity of Meta-analysis in Diabetes: We Need to Be Aware of Its Limitations. Diabetes Care 2013, 36(10), 3361-3367.
• Stevens RJ, Ali R, Bankhead CR, Bethel MA, Cairns BJ, Camisasca RP, Crowe FL, Farmer AJ, Harrison S, Hirst JA, Home P, Kahn SE, McLellan JH, Perera R, Pluddemann A, Ramachandran A, Roberts NW, Rose PW, Schweizer A, Viberti G, Holman RR. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 2012, 55(10), 2593-2603.
• Home P. Cardiovascular Disease and Oral Agent Glucose-Lowering Therapies in the Management of Type 2 Diabetes. Diabetes Technology & Therapeutics 2012, 14(suppl. 1), S33-S42.
• Home PD. Diabetes therapy and prevention of vascular damage. In: Goodfellow J.A, ed. Understanding Medical Research: The Studies That Shaped Medicine. Chichester: Wiley-Blackwell, 2012, pp.235-245.
• Stevens RJ, Ali R, Bankhead CR, Bethel MA, Cairns BJ, Camisasca RP, Crowe FL, Farmer AJ, Harrison S, Hirst JA, Home P, Kahn SE, McLellan JH, Perera R, Pluddemann A, Ramachandran A, Roberts NW, Rose PW, Schweizer A, Viberti G, Holman RR. Erratum to: Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 2012, 55(12), 3399-3400.
• Freemantle N, Balkau B, Danchin N, Wang E, Marre M, Vespasiani G, Kawamori R, Home PD. Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetes. Diabetes, Obesity and Metabolism 2012, 14(10), 901-909.
• Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation, 2012.
• Home PD, Meneghini L, Wendisch U, Ratner RE, Johansen T, Christensen TE, Jendle J, Roberts AP, Birkeland KI. Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes. Diabetic Medicine 2012, 29(6), 716-720.
• Home PD, Almaatouq M. Improving health outcomes in 2011 for people with type 2 diabetes: a report from a symposium held on the occasion of the International Diabetes Federation World Diabetes Congress, Dubai, 5-8 December 2011. Diabetes and Vascular Disease Research 2012, 12(2), 101-108.
• Hall GC, McMahon AD, Carroll D, Home PD. Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study. Pharmacoepidemiology and Drug Safety 2012, 21(3), 305-313.
• Lepercq J, Lin J, Hall G, Dain M-P, Riddle M, Home P. Meta-analysis of maternal and neonatal outcomes associated with the use of insulin glargine versus NPH insulin during pregnancy. Obstetrics and Gynecology International 2012, 2012, 649070.
• Hall GC, McMahon AD, Carroll D, Home PD. Observational study of the association of first insulin type in uncontrolled type 2 diabetes with macrovascular and microvascular disease. PLoS One 2012, 7(1), e49908.
• Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes, Obesity and Metabolism 2012, 14(9), 780-788.
• Hall GC, McMahon AD, Dain MP, Home PD. A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes. Diabetes Research and Clinical Practice 2011, 94(3), 442-448.
• Home P, Naggar NE, Khamseh M, Gonzalez-Galvez G, Shen C, Chakkarwar P, Yang W. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-western countries: The A₁chieve study. Diabetes Research and Clinical Practice 2011, 94(3), 352–363.
• Home P. Biosimilar insulins. Diabetes Voice 2011, 56(2), 40-43.
• Sibal L, Agarwal S, Home P. Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011, 4, 23-34.
• Little S, Shaw J, Home P. Hypoglycemic rates with basal insulin analogs. Diabetes Technology & Therapeutics 2011, 13(Suppl. 1), S53-S64.
• MacDonald MR, Petrie MC, Home PD, Komajda M, Jones NP, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, McMurray JVJ. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes : a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in diabetes (RECORD) study. Diabetes Care 2011, 34(6), 1394-1396.
• MacDonald MR, Petrie MC, Home PD, Komajda M, Jones NP, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, McMurray JJV. Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes: A substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care 2011, 34(6), 1394-1396.
• Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, Lyby K, Jendle JH, Roberts AP, DeVries JH, Meneghini LF. Insulin Degludec in Type 1 Diabetes A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011, 34(3), 661-665.
• National Institute for Health and Clinical Excellence Quality Standards Programme. Quality standard for diabetes in adults. London: NICE, 2011. Q56.
• Home PD. Safety of PPAR agonists. Diabetes Care 2011, 34(Suppl. 2), S215-S219.
• Teoh H, Home P, Leiter LA. Should A1C targets be individualized for all people with diabetes? Arguments for and against. Diabetes Care 2011, 34(Suppl. 2), S191-S196.
• Home P. Structured care for diabetes should cover a spectrum of areas. Berkhamsted: MGP Ltd, 2011. Available at: http://www.eguidelines.co.uk/eguidelinesmain/gip/vol_14/sep_11/home_diabetes_sep11.php.
• Sibal L, Neely R, Jones A, Home P. Friedewald equation underestimates low-density lipoprotein cholesterol at low concentrations in young people with and without Type 1 diabetes. Diabetic Medicine 2010, 27(1), 37-45.
• Home PD. Low-dose rosiglitazone plus metformin reduces risk of incident type 2 diabetes compared with placebo in people with impaired glucose tolerance. Evidence-Based Medicine 2010, 16(1), 10-11.
• Yang W, Zilov A, Soewondo P, Bech O, Sekkal F, Home P. Observational studies: Going beyond the boundaries of randomized controlled trials. Diabetes Research and Clinical Practice 2010, 88(1), 3-9.
• Thomas R, Home P. Recommended management of type 1 diabetes with insulin. Prescriber 2010, 21(14), 14-22.
• Fonseca V, Davidson J, Home P, Snyder J, Jellinger P, Dyhr Toft A, Barnett A. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: A pooled analysis of treat-to-target trials. Current Medical Research and Opinion 2010, 26(7), 1621-1628.
• Sibal L, Agarwal S, Home P, Boger R. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Current Cardiology Reviews 2010, 6(2), 82-90.
• Home PD, Bailey CJ, Donaldson J, Chen H, Stewart MW. A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with type 2 diabetes. Diabetic Medicine 2007, 24(6), 618-625.
• Al-Ozairi E, Sibal S, Home P. Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): Good for Sulfonylureas?. Diabetes Care 2007, 30(6), 1677-1680.
• Dashora UK, Sibal L, Ashwell SG, Home PD. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: A randomized placebo-controlled trial. Diabetic Medicine 2007, 24(4), 344-349.
• Gallagher A, Butler TJ, Home PD. The effect of the optimal use of rapid-acting insulin analogues on insulin secretion in Type 2 diabetes. Diabetes Research and Clinical Practice 2007, 76(3), 327-334.
• Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-Naïve people with type 2 diabetes. Diabetes Care 2006, 29(6), 1269-1274.
• Home P. A digest of the Global Guideline for Type 2 Diabetes. Diabetes Voice 2006, 51(supplement), 1-44.
• Bagust A, Evans M, Beale S, Home PD, Perry AS, Stewart M. A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies. PharmacoEconomics 2006, 24(Suppl. 1), 5-19.
• Sibal L, Huong NL, Gebbie J, Home P. Cardiovascular risk factors predicting the development of distal symmetrical polyneuropathy in people with type 1 diabetes: A 9-year follow-up study. In: Adeghate, E; Saadi, H; Adem, A; Obineche, E, ed. Diabetes Mellitus and Its Complications: Molecular Mechanisms, Epidemiology, and Clinical Medicine. Hoboken, United States: Wiley-Blackwell Publishing Inc, 2006, pp.304-318.
• World Health Organization, International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Geneva: World Health Organization, 2006.
• Home P, IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: Recommendations for standard, comprehensive, and minimal care. Diabetic Medicine 2006, 23(6), 579-593.
• Hanney SR, Home PD, Frame I, Grant J, Green P, Buxton MJ. Identifying the impact of diabetes research. Diabetic Medicine 2006, 23(2), 176-184.
• Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, Shutler SD, Stephens JW, Home PD. Improved glycaemic control with insulin glargine plus insulin lispro: A multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabetic Medicine 2006, 23(3), 285-292.
• Home P, Kurtzhals P. Insulin detemir: From concept to clinical experience. Expert Opinion on Pharmacotherapy 2006, 7(3), 325-343.
• Ashwell SG, Gebbie J, Home PD. Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times. Diabetic Medicine 2006, 23(1), 46-52.
• Sibal L, Huong NL, Gebbie J, Dashora UK, Agarwal SC, Home P. Predicting the development of macrovascular disease in people with type 1 diabetes: A 9-year follow-up study. In: Diabetes Mellitus and Its Complications: Molecular Mechanisms, Epidemiology, and Clinical Medicine. 2006, Al Ain, United Arab Emirates: Wiley-Blackwell Publishing Inc.
• Home PD, Hallgren P, Usadel KH, Sane T, Faber J, Grill V, Friberg HH. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes. Diabetes Research and Clinical Practice 2006, 71(2), 131-139.
• Home P. The diabetes epidemic and the developing world. Practical Diabetes International 2006, 23(8), 325-326.
• Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart. Diabetic Medicine 2006, 23(8), 879-886.
• Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A, Bartusch-Marrain P, Egger T, Francesconi M, Irsigler K, Kazerovsky-Bielesc G, Pieber T, Prager R, Weitgasser R, Saudek F, Laursen HB, Christensen C, Hermansen K, Juhl H, Soelling K, Bergkulla S, Haapamaki H, Harno K, Salmela P, Voutilainen E, Bringer J, Charbonnel B, Charpentier G, Durlach V, Gouet D, Grenier JL, Ozenne G, Penfornis A, Pinget M, Rodier M, Valensi P, Vexiau P, Warnet A, Austenat E, Beyer J, Dreyer M, Haslbeck M, Ittner JR, Landgraf R, Laube H, Lembcke HJ, Liebl A, Lotz N, Matthei S, Palitzsch KD, Paschke R, Usadel KH, Raptis S, de Heide LJM, van Hoogenhuijze J, Lutterman JA, Spooren PFMJ, Dyrbekk D, Vaaler S, Berne C, Eriksson J, Lins PE, Diem P, Gaillard R, Gray RS, Thow JC, Reckless J, Sampson M, Tindall H. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes/Metabolism Research and Reviews 2005, 21(6), 545-553.
• Home P. Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Current Medical Research and Opinion 2005, 21(7), 989-998.
• International Diabetes Federation Task Force on Clinical Guidelines, Home PD [chair]. Global Guideline for Type 2 Diabetes. Brussels, Belgium: International Diabetes Federation, 2005.
• Wilkinson A, Davidson J, Dotta F, Home PD, Keown P, Kiberd B, Jardine A, Levitt N, Marchetti P, Markell M, Naicker S, O'Connell P, Schnitzler M, Standl E, Torregosa J-V, Uchida K, Valantine H, Villamil F, Vincenti F, Wissing M. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clinical Transplantation 2005, 19(3), 291-298.
• Thomas R, Home PD. Insulin therapy for people with Type 1 diabetes. Prescriber 2005, 16(6), 48-58.
• Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, Komajda M, Gubb J, Biswas N, Jones NP. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): Study design and protocol. Diabetologia 2005, 48(9), 1726-1735.
• Gallagher A, Home PD. The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes. Diabetes Research and Clinical Practice 2005, 67(3), 196-203.
• Home PD. Glucose: sweetness and toxin. Diabetes Voice, special issues: Eating 2004, 49, 5-7.
• Consoli A, Gomis R, Halimi S, Home PD, Mehnert H, Strojek K, Van Gaal LF. Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: An evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes and Metabolism 2004, 30(6), 509-516.
• Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg J-E, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E. Insulin Detemir Offers Improved Glycemic Control Compared with NPH Insulin in People with Type 1 Diabetes: A randomized clinical trial. Diabetes Care 2004, 27(5), 1081-1087.
• Boehm BO, Vaz JA, Brondsted L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. European Journal of Internal Medicine 2004, 15(8), 496-502.
• Smith SC, Jackson R, Pearson TA, Fuster V, Yusuf S, Faergeman O, Wood DA, Alderman M, Horgan J, Home P, Hunn M, Grundy SM. Principles for national and regional guidelines on cardiovascular disease prevention - A scientific statement from the World Heart and Stroke Forum. Circulation 2004, 109(25), 3112-3121.
• Home P, Mbanya JC, Horton E. Standardisation of glycated haemoglobin [Editorial]. British Medical Journal 2004, 329(7476), 1196-1197.
• Home PD. A guide to guide diabetes guideline development. Diabetes Voice 2003, 48(3), 18-20.
• DeVries JH, Lindholm A, Jacobsen JL, Heine RJ, Home PD. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes. Diabetic Medicine 2003, 20(4), 312-318.
• Working Party of the International Diabetes Federation (European Region), Members include: PD Home (Chairman), P Senior. Hypertension in people with Type 2 diabetes: Knowledge-based diabetes-specific guidelines. Diabetic Medicine 2003, 20(12), 972-987.
• Home P, European Insulin Glargine Study Gr. A randomized, multicentre trial of insulin glargine versus NPH insulin in people with Type 1 diabetes. In: Diabetologia: 38th EASD Annual Meeting of the European Association for the Study of Diabetes. 2002, Budapest, Hungary: Springer.
• Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: A randomized trial in Type 1 and Type 2 diabetic patients. Diabetic Medicine 2002, 19(5), 393-399.
• Gallagher A, Home PD. The effect of insulin aspart on post-prandial metabolism and lipid profile in Type 2 diabetes. In: Diabetologia: 38th EASD Annual Meeting of the European Association for the Study of Diabetes. 2002, Budapest, Hungary: Springer.
• Dixon S, Morrissey MI, Patel TC, Home PD, Peters JR, Bearne A, Sharplin P, Davies S, Currie CJ. The interaction between frequency of hypoglycaemia, single and multiplevascular complications and health utility. In: Diabetologia: 38th EASD Annual Meeting of the European Association for the Study of Diabetes. 2002, Budapest, Hungary: Springer.
• Boehm B, Home P, Kamp N, Lindholm A. Biphasic insulin aspart and biphasic human insulin compared in Type 2 diabetic subjects. In: 37th Annual Meeting of the EASD. 2001, Glasgow, UK: Springer.
• Amiel S, Home PD, Jacobsen JL, Lindholm A, Insulin Aspart Study Grp. Insulin aspart safe for long-term treatment. In: 37th Annual Meeting of the EASD. 2001, Glasgow, UK: Springer.
• Gallagher A, Home PD. The effect of insulin aspart on postprandial metabolism and metabolic outcome in Type 2 diabetes. In: 37th Annual Meeting of the EASD. 2001, Glasgow, UK: Springer.
• Freeman DJ, Wilson V, Canavan J, Home P, Cox VM. Changes in muscle fibre composition are associated with changes in glucose disposal in a minipig model of Type I diabetes. In: PROCEEDINGS OF THE NUTRITION SOCIETY. 2000.
• Home P, Standl E, Willms B. Guide for type 1 diabetes mellitus. Diabetes und Stoffwechsel 2000, 9(3), 173-204.
• Gallagher A, Home PD. The effect of insulin aspart on metabolic outcomes and albumin excretion in Type 2 diabetes. In: DIABETOLOGIA. 2000.
• Home P. Insulin glargine: The first clinically useful extended-acting insulin in half a century?. Expert Opinion on Investigational Drugs 1999, 8(3), 307-314.
• Home P. Rapid-acting insulin secretagogues: a clinical need?. In: Satellite Symposium on Repaglinide: A New Dimension in the Management of Type 2 Diabetes. 1999, Barcelona, Spain: J. A. Barth Verlag.
• Home P. Untitled - Foreword. Diabetes, Obesity and Metabolism 1999, 1, SV-SV.